{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:51:07Z","timestamp":1791910267784,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtct.2025.04.017","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T15:25:29Z","timestamp":1746458729000},"page":"450.e1-450.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland"],"prefix":"10.1016","volume":"31","author":[{"given":"Alexander","family":"Denk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5662-2630","authenticated-orcid":false,"given":"Matthias Alexander","family":"Fante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard T.","family":"Greinix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria Wagner","family":"Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-4335","authenticated-orcid":false,"given":"Katharina","family":"Egger-Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darina","family":"Kodzhabasheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Halter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Teichert","family":"von L\u00fcttichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz Peter","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inken","family":"Hilgendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Lawitschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Frietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-3190","authenticated-orcid":false,"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jtct.2025.04.017_bib0001","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","article-title":"Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study","volume":"108","author":"Fraser","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.jtct.2025.04.017_bib0002","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.04.017_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jtct.2025.04.017_bib0004","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbmt.2015.05.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report","volume":"21","author":"Martin","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1016\/j.jtct.2025.04.017_bib0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.jtct.2025.04.017_bib0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/bmt.2013.129","article-title":"Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force","volume":"49","author":"Duarte","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.jtct.2025.04.017_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5045\/kjh.2011.46.3.153","article-title":"Treatment of chronic graft-versus-host disease: Past, present and future","volume":"46","author":"Martin","year":"2011","journal-title":"Korean J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.04.017_bib0008","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.bbmt.2019.03.003","article-title":"Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland","volume":"25","author":"Wolff","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"10.1016\/j.jtct.2025.04.017_bib0009","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/bloodadvances.2019000145","article-title":"Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD","volume":"3","author":"Jagasia","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2025.04.017_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"REACH3 Investigators. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.04.017_bib0011","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.2020006892","article-title":"A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease","volume":"137","author":"Curtis","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.04.017_bib0012","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bbmt.2020.05.015","article-title":"Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial","volume":"26","author":"Pidala","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.jtct.2025.04.017_bib0013","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-020-03968-w","article-title":"IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"99","author":"Kattner","year":"2020","journal-title":"Ann Hematol"},{"issue":"25","key":"10.1016\/j.jtct.2025.04.017_bib0014","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.04.017_bib0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00277-021-04434-x","article-title":"Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis","volume":"100","author":"Wertheimer","year":"2021","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.04.017_bib0016","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00277-020-04193-1","article-title":"Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis","volume":"99","author":"Fante","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2025.04.017_bib0017","unstructured":"FDA expands ibrutinib indications to chronic GVHD. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-ibrutinib-indications-chronic-gvhd. Accessed: March 10, 2025."},{"issue":"8","key":"10.1016\/j.jtct.2025.04.017_bib0018","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","article-title":"Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease","volume":"27","author":"Martini","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2025.04.017_bib0019","author":"Wolf"},{"issue":"22","key":"10.1016\/j.jtct.2025.04.017_bib0020","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.04.017_bib0021","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"AGAVE-201 Investigators. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.04.017_bib0022","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.jtct.2025.04.017_bib0023","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbmt.2015.10.009","article-title":"Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation","volume":"22","author":"Williams","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.jtct.2025.04.017_bib0024","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Pavletic SZ; Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"10.1016\/j.jtct.2025.04.017_bib0025","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","article-title":"Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study","volume":"22","author":"Grube","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"10.1016\/j.jtct.2025.04.017_bib0026","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"10.1016\/j.jtct.2025.04.017_bib0027","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/bmt.2012.45","article-title":"Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation","volume":"47","author":"Ruutu","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.jtct.2025.04.017_bib0028","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.04.017_bib0029","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bmt.2017.223","article-title":"Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"53","author":"Giaccone","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"10.1016\/j.jtct.2025.04.017_bib0030","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-019-0544-y","article-title":"Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"54","author":"Axt","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"10.1016\/j.jtct.2025.04.017_bib0031","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.jtct.2025.04.017_bib0032","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2040620713489842","article-title":"Treatment and management of graft-versus-host disease: improving response and survival","volume":"4","author":"Garnett","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.04.017_bib0033","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.04.017_bib0034","doi-asserted-by":"crossref","first-page":"43.e1","DOI":"10.1016\/j.jtct.2021.10.015","article-title":"Efficacy and Safety of Ruxolitinib in Steroid-Refractory\/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges","volume":"28","author":"Redondo","year":"2022","journal-title":"Transpl. Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.04.017_bib0035","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2025.04.017_bib0036","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2008-03-141481","article-title":"A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease","volume":"112","author":"Flowers","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.04.017_bib0037","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood.V92.9.3098","article-title":"Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease","volume":"92","author":"Greinix","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.04.017_bib0038","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1111\/j.1537-2995.2007.01469.x","article-title":"Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature","volume":"47","author":"Kanold","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2025.04.017_bib0039","article-title":"Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtct.2025.04.017_bib0040","article-title":"A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT","author":"DeFilipp","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2025.04.017_bib0041","first-page":"2932","article-title":"Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"141","author":"Koshy","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2025.04.017_bib0042","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672501156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T01:21:02Z","timestamp":1751592062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672501156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S266663672501156X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.04.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}